Overview

Pharmacokinetic Study of 48-hour Sevoflurane Inhalation Using a Disposable Delivery System (AnaConDa©) in Obese ICU Patients

Status:
Completed
Trial end date:
2015-02-01
Target enrollment:
0
Participant gender:
All
Summary
Describing a pharmacokinetic model of 48-h sevoflurane sedation in obese ICU patients
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
University Hospital, Clermont-Ferrand
Treatments:
Sevoflurane
Criteria
Inclusion Criteria:

- Adult patients ventilated more than 48 h Stable respiratory and hemodynamic conditions
Consent of patients or family Arterial line BMI >30

Exclusion Criteria:

- Acute kidney injury BMI <30 Sevoflurane anaphylaxia